item management s discussion and analysis of financial condition and results of operations critical accounting policies the discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements  which have been prepared in accordance with accounting principles generally accepted in the united states 
the preparation of these financial statements requires management to make estimates and assumptions in certain circumstances that affect the reported amount of assets and liabilities  revenues and expenses  and related disclosure of contingent assets and liabilities at the date of our financial statements 
management bases its estimates and judgments on historical experience  observance of trends in the industry  information provided by customers and other outside sources and on various other factors that are believed to be reasonable under the circumstances 
actual results may differ from these estimates under different assumptions or conditions 
revenue recognition the company s revenues are recognized when products are shipped to or otherwise accepted by unaffiliated customers 
the securities and exchange commission s staff accounting bulletin sab no 
 revenue recognition provides guidance on the application of generally accepted accounting principles to selected revenue recognition issues 
the company has concluded that its revenue recognition policy is appropriate and in accordance with generally accepted accounting principles and sab no 
allowance for uncollectible accounts receivable accounts receivable are reduced by an allowance for amounts that may become uncollectible in the future 
the company extends credit to customers in the normal course of business  but generally does not require collateral or any other security to support amounts due 
management performs on going credit evaluations of its customers and bases the estimated allowance on these evaluations 
inventories inventories are stated at the lower of cost first in  first out method or market and have been reduced to lower of cost or market for obsolete  excess or unmarketable inventory 
the lower of cost or market adjustment is based on management s review of inventories on hand compared to estimated future usage and sales 
goodwill  intangible and other long lived assets intangible and certain other long lived assets with a definite life are amortized over their useful lives 
useful lives are based on management s estimates of the period that the assets will generate revenue 
in july  the financial accounting standards board issued sfas which deals with  among other things  amortization of goodwill 
the company adopted this new standard effective july  and ceased amortization of goodwill at that date and reviews goodwill for impairment on a regular basis  at least annually 
management has reviewed goodwill and other intangibles for impairment and has concluded that such assets are appropriately valued at the financial statement date 
recently issued accounting pronouncements in december  the financial accounting standards board fasb issued statement of financial accounting standard sfas no 
 accounting for stock based compensation transition and disclosure 
sfas no 
amends sfas no 
 accounting for stock based compensation  to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock based employee compensation 
in addition  sfas no 
amends the disclosure requirements of accounting principles board apb opinion no 
 interim financial reporting  to require pro forma disclosure in interim financial statements by companies that elect to account for stock based compensation using the intrinsic value method prescribed in apb opinion no 
the company continues to use the intrinsic value method of accounting for stock based compensation 
as a result  the transition provisions will not have an effect on the company s consolidated financial statements 

table of contents in november  fasb issued fasb interpretation no 
fin  guarantor s accounting and disclosure requirements for guarantees  including indirect guarantees of indebtedness of others 
fin addresses the disclosure requirements of a guarantor in its interim and annual financial statements about its obligations under certain guarantees that it has issued 
fin also requires a guarantor to recognize  at the inception of a guarantee  a liability for the fair value of the obligation undertaken in issuing the guarantee 
the disclosure requirements of fin are effective for the company for its quarter ended december  the liability recognition requirements will be applicable prospectively to all guarantees issued or modified after december  other than the additional disclosure requirements  this pronouncement is not expected to have a material impact on our consolidated financial position or results of operation 
in january  fasb issued fasb interpretation no 
fin  consolidation of variable interest entities 
fin is an interpretation of accounting research bulletin no 
 consolidated financial statements  and addresses consolidation by business enterprises of variable interest entities 
fin applies immediately to variable interest entities created or obtained after january  and it applies in the first fiscal year or interim period beginning after june   to variable interest entities in which an enterprise holds a variable interest that it acquired before february  this pronouncement is not expected to have a material impact on our consolidated financial position or results of operation 
in may  the fasb issued statement  accounting for certain financial instruments with characteristics of both liabilities and equity 
statement changes the classifications in the statement of financial position of certain common financial instruments from either equity or mezzanine presentation to liabilities and requires an issuer of those financial statements to recognize changes in fair value or redemption amount  as applicable  in earnings 
sfas is effective for financial instruments entered into or modified after may   and otherwise is effective at the beginning of the first interim period beginning after june  adoption of statement is not anticipated to have an impact on the company s consolidated financial position or results of operations 
general the company manufactures biomaterials and medical devices for use in various surgical markets and provides related specialized contract aseptic manufacturing services 
the company operates through two business units  the hyaluronan division and the oral restorative division 
the company has a number of relationships with corporate partners relating to the development and marketing of hyaluronan based products for a variety of medical applications 
currently  the primary commercial application for the company s hyaluronan is as a component in ophthalmic surgical products marketed by alcon for cataract surgery 
sales to alcon are made under a supply agreement that extends through december  the agreement contains minimum purchase requirements totaling million in each of calendar years and initial sales of intergel solution occurred during fiscal  as ethicon began marketing intergel solution in europe 
on november   the company received fda approval to market intergel solution in the united states 
sales of intergel solution commenced in the united states during the first calendar quarter of intergel solution was voluntarily withdrawn from the market by ethicon in march in order to assess information obtained from post marketing experience 
ethicon is currently working with the company to conduct the review of data relating to the intergel solution post marketing experience in furtherance of its desire to reintroduce the product to the market 
from the clinical analyses performed to date  there is no clinical evidence of problems related directly to intergel solution 
the company s oral restorative division markets a comprehensive line of titanium based dental implants for tooth replacement therapy 
the oral restorative division also manufactures and markets synthetic bone graft substitute products for the restoration of bone tissue deterioration resulting from periodontal disease and tooth loss 
the oral restorative division also markets other products for the regeneration of bone and soft tissue 
the division s products are marketed in the united states through the company s direct sales force  in italy through the company s subsidiary  lifecore biomedical spa in germany through the company s subsidiary  lifecore biomedical gmbh in scandinavia through the company s subsidiary  lifecore biomedical ab and in other countries through distributors 

table of contents results of operations year ended june  compared with year ended june  hyaluronan oral restorative division division consolidated net sales cost of goods sold gross profit operating expenses research and development marketing and sales general and administrative operating income loss net sales 
net sales increased  or in fiscal from fiscal hyaluronan division sales increased  or and oral restorative division sales increased  or 
hyaluronan division sales increased to  in fiscal from  in fiscal due to increased sales of ophthalmic and orthopedic products 
sales of ophthalmic products to a single customer were  in fiscal compared with  for fiscal this sales increase was partially offset by a reduction in intergel solution sales due to ethicon s voluntary withdrawal of intergel solution from the market 
oral restorative division sales increased to  in fiscal from  in fiscal domestic sales increased due to continued growth in market acceptance of the stage single stage implant system and the rbm coated implant lines 
sales in the international markets increased by due to sales increases at our subsidiary operations and a favorable impact from currency translations 
gross profit 
consolidated gross profit  as a percentage of net sales  was in fiscal and in fiscal the gross profit for the hyaluronan division increased to in fiscal from in fiscal the increase in gross profit is due to absorption of unused manufacturing capacity charges associated with increased hyaluronan production and product mix 
gross profit for the oral restorative division increased to in fiscal from in fiscal due to sales mix and reduced material costs 
research and development 
research and development expenses decreased  or in fiscal from fiscal the decrease is due to the decline in consulting and professional fees related to the regulatory review process of intergel solution which received fda approval in fiscal marketing and sales 
marketing and sales expenses increased by  or in fiscal from fiscal the increase was due mainly to costs associated with the international expansion of the oral restorative business 
general and administrative 
general and administrative expenses increased by  or in fiscal from fiscal the increase is principally related to costs associated with subsidiary operations and higher legal expenses in the current period as compared to the same period of last fiscal year 
other income expense 
net other expense decreased  for the current period as compared to the same period of last fiscal year 
the decrease is primarily due to the  increase in other income from currency gains realized on euro denominated intercompany transactions 

table of contents year ended june  compared with year ended june  hyaluronan oral restorative division division consolidated net sales cost of goods sold gross profit operating expenses research and development marketing and sales general and administrative operating loss net sales 
net sales increased  or in fiscal from fiscal hyaluronan division sales increased  or and oral restorative division sales increased  or 
hyaluronan division sales increased to  in fiscal from  in fiscal due to increased sales of intergel solution to ethicon with the approval of intergel solution for sale in the united states 
this sales increase was partially offset by reduced ophthalmic hyaluronan shipments and the termination of the bausch lomb shipments that occurred in fiscal oral restorative division sales increased to  in fiscal from  in fiscal domestic sales increased due to continued growth in market acceptance of the stage single stage implant system and the rbm coated implant lines 
sales in the international markets increased by from sales increases at our subsidiary operations 
gross profit 
consolidated gross profit  as a percentage of net sales  was in fiscal and in fiscal the gross profit for the hyaluronan division decreased to in fiscal from in fiscal charges for unused capacity  associated with the company s hyaluronan production as a result of an unanticipated delay in receiving intergel solution marketing approval in the us from the fda  were million in fiscal and million in fiscal the company expects that its hyaluronan division gross margins will gradually improve as production levels increase to meet the expected demand for hyaluronan 
gross profit for the oral restorative division decreased to in fiscal from in fiscal the decrease is the result of product sales mix 
research and development 
research and development expenses increased  or in fiscal from fiscal the increase resulted principally from consulting and related expenses associated with the regulatory process with the fda for intergel solution 
marketing and sales 
marketing and sales expenses increased by  or in fiscal from fiscal the increase was due mainly to the development and execution of new products  promotions and customer training programs for the oral restorative division and increased costs associated with subsidiary operations 
general and administrative 
general and administrative expenses increased by  or in fiscal from fiscal the increase is principally related to costs associated with subsidiary operations and higher legal expenses in the current period as compared to the same period of last fiscal year 
other income expense 
interest expense was lower in fiscal compared to mainly due to a lower level of borrowings on the line of credit in fiscal interest income decreased due to lower level of cash available for investment  combined with lower interest rates in fiscal 
table of contents liquidity and capital resources inventories consist mainly of finished hyaluronan powder and oral restorative products and related raw materials 
the portion of finished hyaluronan inventory that is not expected to be consumed within the next twelve months is classified as long term inventory 
the finished hyaluronan inventory is maintained in a frozen state and has a shelf life of ten years 
total inventory decreased by  and  in fiscal and as the company decreased production of hyaluronan powder and intergel solution 
intergel solution sales increased in fiscal after the company obtained fda approval to market intergel solution in the united states in november  which also contributed to the decrease in hyaluronan inventory in fiscal the company had positive cash flow from operations in fiscal  and charges for unused manufacturing capacity associated with the company s hyaluronan production were less in fiscal than and in fiscal  these charges are a result of ethicon s voluntary withdrawal if intergel solution from the market and in and they resulted from the unanticipated delay in receiving intergel solution marketing approval in the us from the fda 
unless the company s hyaluronan production volume increases  unused manufacturing capacity charges will continue to negatively impact operating results in fiscal and beyond 
gross margins for the hyaluronan division increased in as production levels and efficiency increased 
marketing and sales expenses for the oral restorative products are expected to continue at a high level  and personnel costs have increased 
on july   the company issued  shares of common stock  with an aggregate value of  in connection with the acquisition of shares of lifecore biomedical ab held by two individuals 
the issuances were completed pursuant to an exemption from registration provided under section of the securities act of on march   the company entered into an agreement with lancet software development  inc whereby lancet agreed to develop an e commerce site for the company to market its products worldwide 
payments due under the agreement may be made in the form of the company s common stock or cash  at the option of the company 
in april  the company issued an aggregate of  shares of common stock to lancet as the first progress payment under the agreement 
in june  the company issued an aggregate of  shares of common stock to lancet as the second progress payment under the agreement 
in october  the company issued an aggregate of  shares of common stock to lancet as the final payment under the agreement 
the number of shares issued to lancet was determined using a formula based on the quoted market value of the common stock as determined on the nasdaq national market 
under the terms of the agreement  lancet exercised the right to have the shares registered for sale 
registration statements on form s were filed and declared effective by the securities and exchange commission in april  august and november the loan agreement between the company and the holder of the industrial development revenue bonds issued to finance the company s chaska  minnesota facility was amended in june to waive the fixed charge coverage ratio and the cash flow coverage ratio through june  with respect to certain of these covenants  the company may be required to obtain further waivers for fiscal there can be no assurance that future waivers will be granted to the company 
the company has a  credit facility with a bank which has a maturity date of december  the agreement allows for advances against eligible accounts receivable and inventories  subject to a borrowing base certificate 
interest is accrued at the prime rate at june   which was  and at the prime rate plus  or  as of june  under a previous credit facility agreement 
at june  and  there were no balances outstanding under the line of credit 
the terms of the agreement require the company to comply with various financial covenants including minimum tangible net worth  liabilities to tangible net worth ratio and net income loss 
at june  and  the company was in compliance with all covenants 
the company s ability to generate positive cash flow from operations and achieve ongoing profitability is dependent upon the continued expansion of revenue from its hyaluronan and oral restorative businesses 
growth in the hyaluronan division is unpredictable due to the uncertainty associated with the future market status of intergel solution  the complex governmental regulatory environment for new medical products and the early stage of certain of these markets 
similarly  expansion of the company s oral restorative division sales is also dependent upon increased revenue from new and existing customers  as well as successfully competing in a more mature market 
the company expects its cash generated from anticipated operations and the availability under the line of credit to satisfy cash flow needs in the near term 
no assurance can be given that the company will maintain positive cash flow from operations 

table of contents while the company s capital resources appear adequate today  the company may seek additional financing in the future 
if additional financing is necessary  no assurance can be given that such financing will be available and  if available  will be on terms favorable to the company and its shareholders 
the company does not have any off balance sheet financing activities 
cautionary statement statements included in this management s discussion and analysis of financial condition and results of operations and elsewhere in this form k  in the letter to shareholders contained in the annual report to shareholders  in future filings by the company with the securities and exchange commission and in the company s press releases and oral statements made with the approval of authorized executive officers  if the statements are not historical or current facts  should be considered forward looking statements made pursuant to the safe harbor provisions of the private securities litigation reform act of such forward looking statements relate to market acceptance and demand for the company s products  future product development plans and timing  the results of clinical trials  fda clearances and the related timing of such  the potential size of the markets for the company s products  future product introductions  future revenues  expense levels and capital needs and the company s ability to successfully negotiate acceptable agreements with its corporate partners 
these statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical earnings and those presently anticipated or projected 
the company wishes to caution readers not to place undue reliance on any such forward looking statements  which speak only as of the date made 
the following important factors  among others  in some cases have affected and in the future could affect the company s actual results and could cause its actual financial performance to differ materially from that expressed in any forward looking statement i the uncertainty associated with the future market status of intergel solution  ii obtaining the necessary regulatory approvals for new hyaluronan and oral restorative products  iii the company s reliance on corporate partners to develop new products on a timely basis and to market the company s existing and new hyaluronan products effectively  iv intense competition in the markets for the company s principal products and v other factors discussed in the risk factors filed as exhibit to this form k 
the foregoing list should not be construed as exhaustive  and the company disclaims any obligation subsequently to revise any forward looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events 
item a 
quantitative and qualitative disclosures about market risk the company invests its excess cash in money market mutual funds and highly rated corporate debt securities 
all investments are held to maturity 
the market risk on such investments is minimal 
receivables from sales to foreign customers are denominated in us dollars 
transactions at the company s foreign subsidiaries are denominated in european euros at lifecore biomedical spa and lifecore biomedical gmbh and are denominated in swedish krona at lifecore biomedical ab 
the company has historically had minimal exposure to changes in foreign currency exchange rates  and as such  has not used derivative financial instruments to manage foreign currency fluctuation risk 
the company s outstanding long term debt carries interest at a fixed rate 
there is no material market risk relating to the company s long term debt 

table of contents 
